Copyright
©The Author(s) 2021.
World J Gastroenterol. Jan 7, 2021; 27(1): 80-91
Published online Jan 7, 2021. doi: 10.3748/wjg.v27.i1.80
Published online Jan 7, 2021. doi: 10.3748/wjg.v27.i1.80
Table 3 Comparative analysis of patients with autoimmune hepatitis concomitant with nonalcoholic fatty liver disease and patients with nonalcoholic fatty liver disease with autoimmune phenomena
Variable | Patients with AIH concomitant with NAFLD (n = 61) | Patients with NAFLD with autoimmune phenomena (n = 34) | P value |
Age, yr | 52.05 ± 11.11 | 43.68 ± 13.71 | < 0.001 |
Male sex, n (%) | 13 (21.3) | 6 (17.6) | |
BMI, kg/m2 | 24.21 ± 3.10 | 24.65 ± 2.02 | |
Laboratory | |||
AST, U/L | 55.03 ± 47.31 | 50.03 ± 29.26 | |
ALT, U/L | 66.62 ± 74.94 | 86.01 ± 62.59 | |
AKP, U/L | 63.00 (45.00, 84.00) | 75.00 (54.00, 87.00) | |
GGT, U/L | 49.27 ± 32.24 | 69.26 ± 44.07 | < 0.05 |
Total bilirubin, mg/dL | 10.20 (8.60, 14.10) | 10.25 (7.40, 13.67) | |
Direct bilirubin, mg/dL | 4.20 (3.20, 5.00) | 3.70 (2.92, 4.65) | |
IgG | 15.60 ± 4.57 | 13.81 ± 2.67 | < 0.05 |
IgM | 1.18 ± 0.45 | 1.28 ± 0.57 | |
Histological steatosis stage, n (%) | |||
S1 | 39 (63.9) | 8 (23.5) | |
S2 | 17 (27.9) | 10 (29.4) | |
S3 | 5 (8.2) | 16 (47.1) | |
Histological fibrosis stage, n (%) | |||
F1 | 17 (27.9) | 6 (17.6) | |
F2 | 22 (36.1) | 14 (41.2) | |
F3 | 16 (26.2) | 11 (32.4) | |
F4 | 6 (9.8) | 3 (8.8) | |
CAP, dB/m | 272.57 ± 44.39 | 293.41 ± 51.04 | < 0.05 |
LSM in total, kPa | 9.34 ± 7.14 | 6.49 ± 2.44 | < 0.05 |
In steatosis S1 | 9.19 ± 8.11 | 5.28 ± 1.88 | < 0.05 |
In steatosis S2 | 7.80 ± 3.47 | 6.31 ± 2.18 | |
In steatosis S3 | 15.76 ± 6.25 | 7.20 ± 2.69 | < 0.01 |
- Citation: Ni XX, Lian M, Wu HM, Li XY, Sheng L, Bao H, Miao Q, Xiao X, Guo CJ, Li H, Ma X, Hua J. Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases. World J Gastroenterol 2021; 27(1): 80-91
- URL: https://www.wjgnet.com/1007-9327/full/v27/i1/80.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i1.80